TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21387002

Group type: EXPERIMENTAL
Intervention: Enumeration task (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection task (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specified number detection task (Experiment 3)
Number of subjects: 0
Study: 18328845

Group type: EXPERIMENTAL
Intervention: Early exercise stress testing (EST) after coronary stenting
Number of subjects: 1000
Study: 16339195

Group type: EXPERIMENTAL
Intervention: 30 nM folic acid (FA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 120 nM folic acid (FA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 240 nM folic acid (FA)
Number of subjects: 39
Study: 14618461

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (NI; n=15)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care (UC; n=21)
Number of subjects: 36
Study: 10916717

Group type: EXPERIMENTAL
Intervention: 3-day family medicine preceptorship
Number of subjects: 137
Study: 9136305

Group type: EXPERIMENTAL
Intervention: Orem‐based nursing care promoting nutritional self-care, provided in patients' homes the week after discharge.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 104
Study: 1358821

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dimethendine maleate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine and Dimethendine maleate
Number of subjects: 0
Study: 6142067

Group type: EXPERIMENTAL
Intervention: Desensitization to sulfasalazine
Number of subjects: 47
Study: 31412770

Group type: EXPERIMENTAL
Intervention: QLB group (0.4 cc/kg of 0.3% ropivacaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: C group (0.4 cc/kg of 0.9% saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: QLB group
Number of subjects: 60
Study: 29943093

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa (100/25 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27765726

Group type: EXPERIMENTAL
Intervention: Trospium chloride (30 mg/250 ml) gastric infusion for 6 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trospium chloride (30 mg) immediate-release tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastric infusion of trospium chloride
Number of subjects: 0
Study: 24700526

Group type: EXPERIMENTAL
Intervention: Maitland grade III anterior‐to‐posterior joint mobilization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 21987386

Group type: EXPERIMENTAL
Intervention: Upfront zoledronic acid (4 mg intravenously every 6 months for 5 years)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Delayed-start zoledronic acid (4 mg intravenously every 6 months for 5 years)
Number of subjects: 602
Study: 20300023

Group type: EXPERIMENTAL
Intervention: Chest press on Swiss ball
Number of subjects: 16

Group type: COMPARATOR
Intervention: Chest press on bench
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Shoulder press on Swiss ball
Number of subjects: 16

Group type: COMPARATOR
Intervention: Shoulder press on bench
Number of subjects: 16
Study: 18824714

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus bevacizumab
Number of subjects: 363

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 363
Study: 15907848

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day) and Vitamin E (400 IU/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11874164

Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Baseline naive CD4+ cell count
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 210
Study: 11350109

Group type: EXPERIMENTAL
Intervention: 1.5 million IU streptokinase
Number of subjects: 447
Study: 9420390

Group type: EXPERIMENTAL
Intervention: Methylprednisolone and prednisolone alternated with chlorambucil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Symptomatic treatment only (Control)
Number of subjects: 30
Study: 8320005

Group type: EXPERIMENTAL
Intervention: Soft laser treatment (As-Ga and He-Ne)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 28
Study: 3529799

Group type: EXPERIMENTAL
Intervention: Oral physostigmine (10 mg/day for 3 days)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oral neostigmine (45 mg/day for 3 days)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous physostigmine (1 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous neostigmine (1.5 mg)
Number of subjects: 7
Study: 29080210

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (ExQW)
Number of subjects: 0
Study: 26890454

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional rotating drills
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 40
Study: 26214887

Group type: EXPERIMENTAL
Intervention: Gukang Capsules plus Calcium Carbonate Tablets
Number of subjects: 108

Group type: COMPARATOR
Intervention: Calcium Carbonate Tablets
Number of subjects: 108
Study: 23953056

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/d continuously
Number of subjects: 233

Group type: COMPARATOR
Intervention: Lapatinib 1250 mg/d continuously plus capecitabine 2000 mg/m2 per day on days 1-14 of each 21-d cycle
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 233

Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine
Number of subjects: 233
Study: 21148503

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 326

Group type: COMPARATOR
Intervention: Chloroquine (50 mg/kg, 6 divided doses over 3 days)
Number of subjects: 326
Study: 18324564

Group type: EXPERIMENTAL
Intervention: Menthol cigarette smoking
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Pharmacotherapy-aided quit attempt
Number of subjects: 1343
Study: 17718286

Group type: EXPERIMENTAL
Intervention: Chula-clamp
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard manual compression
Number of subjects: 140
Study: 12665973

Group type: EXPERIMENTAL
Intervention: EX70 (70 eccentric contractions)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: EX30 (30 eccentric contractions)
Number of subjects: 26

Group type: COMPARATOR
Intervention: CON (control group)
Number of subjects: 26
Study: 11212413

Group type: EXPERIMENTAL
Intervention: Sevoflurane with oxygen and 67% nitrous oxide
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Isoflurane with oxygen and 67% nitrous oxide
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Enflurane with oxygen and 67% nitrous oxide
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (oxygen, 50% nitrous oxide, and original concentration of each volatile anesthetic)
Number of subjects: 70
Study: 8922792

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg daily (with some patients receiving 800 mg for part of treatment)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fluconazole 800 mg daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fluconazole therapy
Number of subjects: 27
Study: 1562701

Group type: EXPERIMENTAL
Intervention: Screening for lung cancer, two examinations per year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for lung cancer
Number of subjects: 0
Study: 30028033

Group type: EXPERIMENTAL
Intervention: Posttraumatic cognitions regarding the self, world, and self-blame
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: PTSD symptoms
Number of subjects: 290

Group type: COMPARATOR
Intervention: Demographics
Number of subjects: 290
Study: 28167470

Group type: EXPERIMENTAL
Intervention: Clopidogrel with Shexiang baoxin pills therapy
Number of subjects: 131

Group type: COMPARATOR
Intervention: Clopidogrel therapy (Control)
Number of subjects: 131
Study: 26319228

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) infusion set (microneedle design B)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) infusion set (Rapid-D)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intradermal (ID) infusion set
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) devices (MiniMed and Animas pumps)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) and Subcutaneous (SC) infusion sets
Number of subjects: 43
Study: 23381675

Group type: EXPERIMENTAL
Intervention: Semi-mechanical (SM) group
Number of subjects: 155

Group type: COMPARATOR
Intervention: Hand-sewn (HS) group
Number of subjects: 155

Group type: COMPARATOR
Intervention: Circular stapled (CS) group
Number of subjects: 155
Study: 20687305

Group type: COMPARATOR
Intervention: pacifier‐activated‐lullaby system (PAL) with one 15‐minute trial
Number of subjects: 68

Group type: COMPARATOR
Intervention: pacifier‐activated‐lullaby system (PAL) with three 15‐minute trials
Number of subjects: 68

Group type: COMPARATOR
Intervention: pacifier‐activated‐lullaby system (PAL)
Number of subjects: 68
Study: 19090877

Group type: EXPERIMENTAL
Intervention: Trandolapril/verapamil SR (T/V) fixed-dose combination (FDC)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Benazepril/amlodipine (B/A) fixed-dose combination (FDC)
Number of subjects: 304
Study: 16868321

Group type: EXPERIMENTAL
Intervention: Injection of 1 mL of 2% prilocaine using the peppering technique
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1 mL of 2% prilocaine combined with 2 mL of autologous blood
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1 mL of 2% prilocaine mixed with 40 mg of methylprednisolone acetate
Number of subjects: 44
Study: 12956200

Group type: EXPERIMENTAL
Intervention: Ciclopirox nail lacquer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amorolfine nail lacquer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of nail lacquer with oral antifungal agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other topical agents
Number of subjects: 0
Study: 11130156

Group type: EXPERIMENTAL
Intervention: 12-step attendance
Number of subjects: 99
Study: 8862011

Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Idarubicin (IRR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group 1 (P‐gp negative)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group 2 (P‐gp positive)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Idarubicin (IRR) in group 2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) in group 2
Number of subjects: 50
Study: 1621484

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 8
Study: 6142748

Group type: EXPERIMENTAL
Intervention: Oral salbutamol 4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral pirbuterol 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (500 microgram and 5 mg)
Number of subjects: 12
Study: 31541454

Group type: EXPERIMENTAL
Intervention: Nonrandomized real-world evidence (RWE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study: 28986072

Group type: EXPERIMENTAL
Intervention: Medication abortion
Number of subjects: 643

Group type: COMPARATOR
Intervention: Aspiration abortion
Number of subjects: 643
Study: 26785362

Group type: EXPERIMENTAL
Intervention: Display ban condition
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Plain packs and ads
Number of subjects: 1313
Study: 25456022

Group type: EXPERIMENTAL
Intervention: Cumin powder (3 g/d with yogurt for 3 months)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (yogurt without cumin powder for 3 months)
Number of subjects: 88
Study: 22217980

Group type: EXPERIMENTAL
Intervention: Fine emulsion infused in duodenum
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fine emulsion infused in ileum
Number of subjects: 15

Group type: COMPARATOR
Intervention: Coarse emulsion infused in duodenum
Number of subjects: 15

Group type: COMPARATOR
Intervention: Coarse emulsion infused in ileum
Number of subjects: 15
Study: 23051942

Group type: EXPERIMENTAL
Intervention: Mind Sound Technology (MST)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-practitioners (Control)
Number of subjects: 42
Study: 16319909

Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 14741074

Group type: EXPERIMENTAL
Intervention: Sympathyl (study drug)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 11048827

Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control
Number of subjects: 127
Study: 9076210

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (gelatin)
Number of subjects: 17
Study: 8093113

Group type: EXPERIMENTAL
Intervention: 60 Gy in 30 fractions
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: 30 or 36 Gy in 10 or 12 fractions
Number of subjects: 941

Group type: COMPARATOR
Intervention: 20 Gy in five fractions
Number of subjects: 941
Study: 3081600

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 0
Study: 30941472

Group type: EXPERIMENTAL
Intervention: Interventional closure of a patent foramen ovale (PFO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiplatelet therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral anticoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PFO occluder implantation
Number of subjects: 0
Study: 27460262

Group type: EXPERIMENTAL
Intervention: Pectin-coated fortified rice with 400 μg 13C5-PteGlu
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Uncoated fortified rice with 400 μg 13C5-PteGlu
Number of subjects: 26

Group type: COMPARATOR
Intervention: Aqueous 400 μg 13C5-PteGlu
Number of subjects: 26
Study: 26111104

Group type: EXPERIMENTAL
Intervention: Epirubicin and Cyclophosphamide (EC)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF)
Number of subjects: 198

Group type: COMPARATOR
Intervention: nab-Paclitaxel and Capecitabine (nPX)
Number of subjects: 198
Study: 23885722

Group type: EXPERIMENTAL
Intervention: Isoosmolar enema (Normosol-R)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hyperosmolar enema (Fleet)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hypoosmolar enema (distilled water)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All enema types
Number of subjects: 9
Study: 21246188

Group type: EXPERIMENTAL
Intervention: Esmirtazapine 1.5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Esmirtazapine 4.5 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 32
Study: 19513170

Group type: EXPERIMENTAL
Intervention: Active group received training to assess and teach correct inhaler techniques and were provided with patient education tools.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group delivered standard care without additional training.
Number of subjects: 31
Study: 17886555

Group type: COMPARATOR
Intervention: High-frequency rTMS at 5 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-frequency rTMS at 10 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-frequency rTMS at 1 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (5 or 10 Hz) in noncerebral lesions
Number of subjects: 0
Study: 16317969

Group type: EXPERIMENTAL
Intervention: Custom trays with 10% carbamide peroxide gel worn overnight for 2 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: 10% hydrogen peroxide polyethylene strips worn for 30 minutes twice a day for 2 weeks
Number of subjects: 57
Study: 16212329

Group type: EXPERIMENTAL
Intervention: Rectangular titanium cages
Number of subjects: 36

Group type: COMPARATOR
Intervention: Iliac crest autograft
Number of subjects: 36
Study: 9596324

Group type: EXPERIMENTAL
Intervention: Atropine premedication (0.6 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline placebo (1 mL)
Number of subjects: 100
Study: 7674696

Group type: EXPERIMENTAL
Intervention: Current therapies for acute ischemic syndromes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effective organization of systems
Number of subjects: 0
Study: 1982831

Group type: EXPERIMENTAL
Intervention: EPO subcutaneous route (s.c) at doses of 20 u/kg daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: EPO subcutaneous route (s.c) at doses of 2000 units twice a week
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: EPO intraperitoneal route (i.p) at doses of 4000 u/day, three days a week
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of EPO doses and outcomes between groups
Number of subjects: 19
Study: 369361

Group type: EXPERIMENTAL
Intervention: 1 mg atropine sulfate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2 mg glucagon
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31053157

Group type: EXPERIMENTAL
Intervention: Blended internal-external facilitation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (non-intervened sites)
Number of subjects: 9
Study: 27942980

Group type: EXPERIMENTAL
Intervention: Self-paced maximal exercise protocol (SPV)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Traditional ramp protocol (RAMP)
Number of subjects: 44
Study: 26111923

Group type: EXPERIMENTAL
Intervention: Tailored post-session D-cycloserine (DCS) administration
Number of subjects: 156

Group type: COMPARATOR
Intervention: Untailored post-session D-cycloserine (DCS)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Untailored pre-session D-cycloserine (DCS)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) prior to fear extinction retention experiment
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo prior to fear extinction retention experiment
Number of subjects: 156
Study: 24019551

Group type: EXPERIMENTAL
Intervention: GM2-KLH/QS-21 vaccination
Number of subjects: 1314

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1314
Study: 21613440

Group type: EXPERIMENTAL
Intervention: Cam-type deformities
Number of subjects: 2081

Group type: EXPERIMENTAL
Intervention: Pincer-type deformities
Number of subjects: 2081

Group type: EXPERIMENTAL
Intervention: Crossover sign
Number of subjects: 2081
Study: 19906504

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 473

Group type: COMPARATOR
Intervention: acarbose
Number of subjects: 473
Study: 16947097

Group type: EXPERIMENTAL
Intervention: Written advice from the paediatrician
Number of subjects: 40

Group type: COMPARATOR
Intervention: No additional information about cotinine levels
Number of subjects: 40
Study: 15230794

Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg intramuscular)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hyoscine (20 mg intramuscular)
Number of subjects: 72
Study: 11878523

Group type: EXPERIMENTAL
Intervention: Epidural 0.2% bupivacaine 8 ml h(‐1) (bupi group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural 0.2% bupivacaine/morphine 50 microg at 4 ml h(‐1) (bupi/morph group)
Number of subjects: 40
Study: 9621380

Group type: EXPERIMENTAL
Intervention: Early amniocentesis
Number of subjects: 212

Group type: COMPARATOR
Intervention: Transabdominal chorionic villus sampling
Number of subjects: 212
Study: 8169617

Group type: EXPERIMENTAL
Intervention: Nimodipine administration
Number of subjects: 852
Study: 2656527

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 125552

Group type: EXPERIMENTAL
Intervention: Mebendazole (Vermox)
Number of subjects: 0
Study: 31233255

Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide (average dose of 7.2µg per day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide (test phase)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide (long-term follow-up)
Number of subjects: 20
Study: 27914822

Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate 16 g/m2 intravenously 6 hours after each cisplatin dose
Number of subjects: 125

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Number of subjects: 125
Study: 25711323

Group type: EXPERIMENTAL
Intervention: Participants with at least one CVD risk factor
Number of subjects: 4019

Group type: EXPERIMENTAL
Intervention: Participants with two or more CVD risk factors
Number of subjects: 4019

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 4019

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 4019

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 4019

Group type: EXPERIMENTAL
Intervention: Prevalence of at least one risk factor by region
Number of subjects: 4019
Study: 22880056

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group training for UPS
Number of subjects: 162
Study: 20032496

Group type: EXPERIMENTAL
Intervention: (SC)GOS/(LC)FOS/AOS (1.5 g . kg(‐1) . d(‐1))
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 113
Study: 18824757

Group type: EXPERIMENTAL
Intervention: BITA in situ grafting
Number of subjects: 481

Group type: COMPARATOR
Intervention: BITA Y configuration
Number of subjects: 481
Study: 15819987

Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (DTI) analysis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of IVC + and IVR < 1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Controls (no intervention)
Number of subjects: 45
Study: 11835452

Group type: EXPERIMENTAL
Intervention: Nabilone (synthetic cannabinoid receptor agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10078893

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted pelvic floor muscle training
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 8625134

Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no GM‐CSF)
Number of subjects: 11